News & Views
Phibro Animal Health acquires fish vaccine business KoVax
TEL AVIV, Israel - Phibro Animal Health Corporation has acquired KoVax Ltd., an Israel-based developer and manufacturer of vaccines for the global aquaculture market.
December 21, 2018 By Hatchery International Staff
The acquisition expands Phibro’s portfolio of aquaculture products.
KoVax’s research and development team has joined Phibro’s biological R&D team, and will focus on developing a pipeline of innovative vaccines for the aquaculture market, according to a release. Phibro’s first commercial aquaculture vaccine is KoVax’s “KV3” vaccine, which helps prevent Koi Herpes Virus, a highly contagious disease that can cause significant mortality in common carp farms.
“The acquisition of KoVax’s strong vaccine portfolio, including KV3 and products currently in development, will empower Phibro to provide our customers with customized solutions to meet their unique challenges,” said Phibro’s vice-president of Aquaculture, Dr. Raanan Ariav.
“I am extremely proud that the years of hard work and creativity our team has brought to developing aquaculture vaccines is recognized by a leading animal health company like Phibro,” said Orit Kotler, who co-founded KoVax with her husband Yaniv. “I am very confident that my team will quickly find themselves at home within the Phibro organization and thrilled with the opportunities to expand the pace and range of their development work. This is a win for aquaculture innovation and fish health.”
Print this page
